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DETAILED INFORMATION ON FAVIPIRAVIR: DRUG FOR TREATMENT OF SARS-COV-2
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Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) is another name given to pandemic disease COVID-19 that is caused by a newly 
discovered coronavirus. People infected with coronavirus will experience mild-to-moderate respiratory illness, and it can be seen in a serious stage 
when comorbidities include along with it. This is now creating a huge pandemic situation all over the world with a huge rate of sufferers, that is, around 
9.06 million around the world and about 440 k in India till today according to the World Health Organization. This is a serious condition that should 
be solved with vaccine only as coronavirus is undergoing mutation it makes difficult to invent a vaccine for it. So far, about 200 genetic mutations have 
been discovered across the world also in these 198 mutations appeared independently more than once. Due to this pandemic situation, there are so 
many clinical trials going on in discovering vaccines. Recently, after many trails conducting favipiravir are found to be the most successful in treating 
any stage of SARS-CoV-2. This article focuses completely on this area, along with its mechanism, side effects, uses, and contraindications.
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INTRODUCTION
Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) is 
caused by a coronavirus. The structure consists of spikes which are 
a type of protein that is most essential in causing infection to human 
cells. Furthermore, spikes now are undergoing tremendous changes 
in a structure known as mutations that change the entire function and 
properties of the virus and lead to the production of new strain about 
14 strains due to mutations in spikes. Beta-coronavirus has three major 
classes that made zoonosis diseases that include SARS-CoV-2 that 
occurred in 2002, infected 8000 people, and killed 800 next again after 
10 years in 2012 MERS-CoV caused a highly lethal effect about 35% 
mortality rate now another class SARS-CoV-2 emerged with heavy loss to 
human health all over the world and also caused huge loss economically 
[1]. The novel coronavirus is showing a high rate of mutations; still, 
there are any researches going on to discover more strains. Due to the 
pandemic and the situations, the World Health Organization has declared 
the situation as Public Health Emergency of International Concern [2].
Commonly, all viruses mutate, but speed rate is important in discovering 
vaccines. Most virus mutations do not change viral protein referred 
to as silent mutations, while other mutations change the amino acid 
sequence of viral protein. Even change in sequence does not affect 
functionally, so these are called inert also some mutations make viruses 
functionally different making a lineage of a virus [3] Fig. 1 [4].
INFLUENCE OF STRAINS IN VACCINE
When different strains are evolving, it becomes difficult to invent 
vaccines as the vaccine provides long-term protection. Normally dose, 
DNA, and MVA-vaccines encode S glycoprotein neutralizes antibodies 
also N protein (induce long-lived memory T cells) in the case of MERS 
and SARS. So now, this aspect became a potentially viable alternative 
long term T-cell immunity against in coronavirus [5].
The strain that is inert will preserve the features that will provide 
immunity against a whole group of variants which make it easier to 
study and make a perfect unique target in discovering vaccines against 
it [6]. As there are more mutations in SARS-CoV-2, an RNA vaccine can 
be more powerful than involves supplementing a similar section of the 
genome in the form of RNA into the host body [7].
PHASES IN DEVELOPMENT OF VACCINE
When they find a new vaccine towards any disease, they need to undergo 
the following process before getting that vaccine into the market:
•	 Pre-clinical tests: This includes the primary stage first done in vitro 
(test tube or cell culture) and also in vivo (animals). This process 
helps testing preliminary efficacy, toxicity, pharmacokinetics, and 
safety information of vaccines. When this stage passes, then they 
can try for the next step on human [10].
•	 Phase – 1: In this phase, they conduct rails in 20–80 humans for 
several months watching regularly. This phase has a significance 
in tracing out the highest dose, side effects, and the best route of 
administration [11].
•	 Phase – 2: Here, experiments will be done on 25–100 people that 
they categorize them into different groups and compare the studies 
between them and intervein the results.
•	 Phase – 3: In this site, the study size is increased to 3000 participants 
and this is the last phase of clinical trials and when this passes that 
they give the approval to release the drug into the market [12].
•	 Approval: After phase-3 trials, the candidate who performs the 
experiments applies for approval of his vaccine to release it into 
the market. However, when there occurs a pandemic situation that 
vaccines can be approved under emergency authorization [13].
FAVIPIRAVIR IN SARS-COV-2
The Drug Controller General of India has approved favipiravir as 
emergency medical use on June 19, in India. Favipiravir is the first 
oral approved medicine in India for treating SARS-CoV-2 launched by 
Glenmark Pharmaceuticals with the name FabiFlu for conducting Phase 
3 clinical trials in patients with mild-to-moderate symptoms [8]. Hence, 
it is important to know about side effects mechanism and details about 
favipiravir.
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It became a challenge for scientists all over the world to 
discover vaccines with no side effects after performing many 
experiments in different phases and by a comparative study between 
many drugs they have discovered favipiravir is the most effective drug
 in treating SARS- CoV-2 [8]. Other drugs work in treating the condition of 
SARS-CoV-2 such as dexamethasone, lopinavir/ritonavir, ivermectin, and 
remdesivir [9].
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STRUCTURE
Favipiravir is a new RNA polymerase inhibitor that is previously used 
in treating influenza-A and B. It also works as an antiviral ebolavirus, 
sand virus, bunia virus, and rabies virus [14]. The chemical structure 
is known as T-705; 6-fluoro-3-hydroxy-2-pyrazine carboxamide 
(pyrazine carboxamide derivative). This undergoes intracellular 
phosphoribosylation to form an active substance that is favipiravir 
ribofuranosyl-5’-triphosphate (favipiravir-RTP) [14], as shown in 
Fig. 2 [15].
MECHANISM
The active form, that is, favipiravir RTP interacts with RNA dependent 
RNA polymerase to inhibit replication of viral genome in host cells. 
Furthermore, from another hypothesis, it is thought to be that the active 
form can be incorporated into the nascent RNA strand and prevents its 
elongation and viral proliferation an transcription [16].
DOSAGE
Dosage includes 200 mg*9 tabs on 1st day followed by 200 mg*4 tablets 
for next 14 days [17].
From the preliminary report by Japan, it is clear that when they 
performed an observational study they found that about 73.8% of mild, 
66.6% of moderate, and 40.1% of the severe condition of SARS-CoV-2 
had improved their condition after 7 days start of favipiravir; improved 
outcome after 14 days for mild cases is 87.8%, for moderate cases is 
84.5%, for severe cases is 60.3% also more than 50% of patients with a 
mild infection, 42.7% with moderate, and 14.7% with severe infection 
had discharged alive from hospital [18].
PHARMACOKINETICS
According to studies from japan on protein binding capacity in 
human serum albumin is about 65% and to α1-acid glycoprotein 
is 6.5% it is found that the maximum plasma concentration of 
favipiravir is 2 h from oral administration while the half-life is 
2–5.5 h [19].
Distribution
As favipiravir is a prodrug and its activation occurs in the liver; also, the 
volume of distribution will be different between prodrug (favipiravir) 
and active metabolite (favipiravir-RTP). There are still ongoing 
experiments at the clinical trial stage [20]. However, for favipiravir, the 
volume of distribution is 15–20 mL [21].
Fig. 2: Intracellular phosphoribosylation [15]
Absorption
The bioavailability is about 97.6% and the Cmax is 51.5 
µg/mL. Favipiravir has many interactions with 200 types of food 
items  that  decrease  Cmax  so  to  compensate  tis  the  dose  needs  to  be 
increased  [16].  Drug-drug  interactions  can  lead  to  serious 
conditions,  especially  in  patients  with  comorbidities  and 
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Metabolism
Normally, all the antivirals undergo hydroxylation primarily by aldehyde 
oxidase and also by xanthine (minimum effect) [22]. From studies, it 
is found that human liver microsomes are sites for hydroxylation that 
forms favipiravir hydroxylate at a range of 3.98–47.6 pmol/mg protein/
min. The range may vary with the average of aldehyde oxidase activity 
by 12 times to maximum [23]. Along with hydroxylating, glucuronate 
conjugate is also observed in human plasma [24].
Excretion
It is excreted through urine in hydroxylate form also a little amount of 
unchanged drug in the ratio of 53.1%:0.8%, respectively [23].
Toxicity
There is no information about toxicity levels in humans, while in 
another family, there is information as follows: Lethal dose for oral and 
intravenous in mice is estimated more than 2000 mg/kg, the lethal dose 
for oral administration in rats is >2000 mg/kg, and lethal dose for dog 
and monkeys is >1000 mg/kg [21].
Symptoms of overdose
Reduced body weight, vomiting, and decreased locomotor activity. 
While when it comes to dogs, rats, and monkeys with oral administration 
that include decreased red blood cells; increased liver function 
parameters such as AST, ALP, ALT, and bilirubin; increased vacuolation 
in hepatocytes; also, testis toxicity is also observed [22].
Pregnancy and lactation
Favipiravir is teratogenic, so it is contraindicated in pregnancy and also 





As it is excreted through urine in different forms, it should be monitored 
in patients with renal failure. However, the dosage is still under clinical 
trials [23].
Use in pediatrics
The efficacy and safety of children are not found yet [23].
Adverse drug reactions
Increased blood uric acid, hypersensitivity reactions, and a little effect 
on the respiratory system, blurred eye vision, and vertigo.
Monitoring parameters in patients with:
Shock, anaphylaxis, pneumonia, hepatitis, jaundice, acute kidney 
disease, decreased WBC, neurological and psychiatric symptoms, colitis 
hemorrhage [23].
List of contraindicated drugs: 
There is a big list of drugs that interact with favipiravr and has an effect 
on pharmacokinetics and pharmacodynamics. The list can be checked 
here (drug bank) [21].
DISCOVERY
Favipiravir has been used as an anti-influenza virus that ranged from 
0.013 to 0.48 µg/ml for influenza A virus, from 0.039 to 0.089 µg/ml 
cells are inoculated with seasonal influenza viruses and seen for the 
lethal effects.
The cell data are shown in Table 1.
The clinical research method includes the assay with XXT. XXT is 
first converted to aqueous formazan by an enzyme in cells, in which 
we are looking for testing. The compounds are then diluted to the 
concentration like the volume of 100 µl with test medium in 96 well-
cultured plates that contain a concentration of 2×103cells/100 µL. The 
test plate is incubated for 3 days at 37°C in 100% humidity and 5% 
CO2. After 3 days, 50 µl of XXT reagent that contains 1 mg/ml in FCS 
free EMEM containing 5 Mm phenazine methosulfate is added, and the 
reaction product is assayed [26].
RECENT UPDATES ON FAVIPIRAVIR IN SARS-COV-2 TREATMENT
There are many clinical trials going on in different countries all over the 
world and different stages. The list is as follows:
•	 From clinical study to evaluate, the performance and safety of 
favipiravir in COVID-19 that has been conducting from March 2020. 
It is randomized, double-blind and placebo-controlled (1:1), the 
screening process is done from 10 days after the onset of COVID-19. 
Here, there is given favipiravir with 1800 mg BID on 1st day and 600 
mg TID for the next 14 days and the other groups were given with 
placebo with the same dose. These groups are made a comparative 
study to evaluate the efficacy of favipiravir in 100 subjects. In this, I 
subject has any renal impairment that the dose has decreased to 600 
mg BID even then if adverse reactions continue then the subject is 
discontinued from treatment. Still, the trail is in Phase 3 in Italy, for 
the outcome of clinical recovery for the time frame of 90 days [27].
•	 From a multi-center, randomized, double-blind, and placebo-
controlled, Phase 3 study evaluating favipiravir for treatment of 
COVID-19 started from May 2020 for the outcome of recovery with 
a time frame of 28 days with favipiravir or placebo administration 
to normalize the conditions such as respiratory rate, SPO2, and 
relief from cough. With the administration of favipiravir combined 
with supportive care with a dose of 1800 mg*2 for day-1 and with 
600 mg*3 for the next 14 days and other with placebo according to 
current national/local guidelines. This is going on in China, Germany, 
and Romania [28].
•	 Another study of the use of favipiravir in hospitalized subjects with 
COVID-19 conducting in the United States starting from April 2020 
to determine the effect of favipiravir plus standard of care (SOC) with 
that of the only SOC on viral clearance of COVID-19 as measured by 
nasopharyngeal and oropharyngeal sampling for the time frame of 
29 days. The interventional study is in Phase 2 by administering 1800 









Inhibition of viral replication 
of influenza A virus (A/Hong 
Kong/213/03 [H5N1]) and 
influenza A virus (A/Ann 
Arbor/6/60 [H2N2]) hybrid 
virus in MDCK cells by neutral 
red uptake assay
Vero cells Function 
assay
7–8 days Antiviral activity against 
Junin virus Candid-1 in Vero 
cells assessed as inhibition of 
virus-induced visual cytopathic 





Inhibition of influenza 
A virus (A/duck/
Minnesota/1525/1981 [H5N1]) 
replication in MDCK cells by 
neutral red uptake assay
When favipiravir toxicity occurs, it still worsens the situation in 
liver functioning. Hence, the doe should be maintained.
Table 1: 
for influenza B virus, and 0.030 to 0.057 µg/ml for influenza C virus. 
The mammalian cell lines like Madin-Darby Canine Kidney Cells (MDCK 
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mg BID favipiravir plus SOC or SOC alone on day-1 then 1000mg 
BID favipiravir plus SOC or SOC alone for the next 13 days, but if the 
subject is suffering from any liver impairment dose was decreased 
to 800 mg BID. The study is done for 14 days treatment follow-up 
for the next 46 days in about 50 patients in three different sites of 
the US for the outcome [29].
•	 The completed clinical trial on the study of safety and efficacy 
of favipiravir in management of COVID-19 started in April and 
completed on June 1 2020 in about 100 subjects for the outcome of 
viral clearance at 14 days’ time frame by conducting PCR analysis 
test at 48–72 h apart and also clinical improvement at 14 days’ time 
frame by administering favipiravir at 3200 mg (1600 mg 12 hourly) 
on day-1 then 1200 mg (600 mg 12 hourly daily) for 10 days and in 
another group for comparison by administering oseltamivir 75 mg 
12 hourly for 5–10 days and hydroxychloroquine 400 mg 12 hourly 
day1 followed by 200 mg 12 hourly for day 2-day10 and comparison 
was done between these groups done in Egypt [30].
•	 By study on oral favipiravir compared to placebo in subjects with 
mild COVID-19 going from April 2020 in Phase 2 randomized, double-
blinded, and placebo-controlled study of oral favipiravir comparing 
with the SOC in subjects with mild or asymptomatic COVID-19 by 
administering SOC plus favipiravir for 10 days and evaluated for 28 
days and in another group SOCplus placebo that is equal to favipiravir 
for 10 days and evaluated for 28 days for the study done by US [31].
Many clinical trials are going on, but few are listed above others can be 
seen on the clinicaltrails.gov website.
Even there are some conditions, where favipiravir is used in treating the 
condition of pneumonia progression and cytokine increase and also to 
improve the condition of respiratory function and produce immediate 
relief from critical or severe conditions even [32].
Future health care, a pharma company has announced to launch 
favipiravir drug under the brand name XARAVIR to treat mild and 
moderate COVID-19 cases [33].
COMBINATION THERAPY
With methylprednisolone
When favipiravir, along with methylprednisolone, was administered 
in patients with a severe condition of COVID-19 and they are on the 
ventilator as they have SPO2 <93% which have been recovered well 
and even they do not require ventilator further but the administration 
should be started in early-stage only to achieve favorable outcomes [34].
With umifenovir
Glenmark has approved that an antiviral combination can effectively 
be used in high viral loads in the early stage of the disease such as 
umifenovir that has that the combined effect has a comprehensive 
antiviral cover on the pre-entry and post-entry life cycle of SARS-CoV-2. 
The combination has shown its effectiveness in clinical trials, and 
further studies are carrying on [35].
CONCLUSION
For SARS-CoV-2, there are still many drugs that are being discovered 
that are in several stages of trails, but favipiravir is the first oral drug that 
is launched by Glenmark. There are still trails going on for combination 
therapy with favipiravir, hoping for good results to discover them. This 
article gives detailed information about favipiravir.
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